Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma

Journal of the Pakistan Medical Association

Volumn 59, Issue 11, 2009, Pages 736-740

  Azam, Muhammad ^a   Qureshi, Asim ^a   Mansoor, Samina ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 70350459099     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001; 94: 153-156
2. Moore DH, Moore DH II, Moore CT. Breast carcinoma etiological factors. Adv Cancer Res 1983; 40: 189-253.
3. Skolnick MH, Cannon-Albright LA. Genetic predisposition to breast cancer. Cancer 1992; 70: 1747-1754
4. Pathak DR, Osuch JR, HE J. Breast carcinoma etiology: current knowledge and new insight into the effects of reproductive and hormonal risk in black and white populations. Cancer 2000; 88: 1230-1238
5. Kelsey JL, Gammon MD. The epidemiology of breast cancer.CA Cancer J Clin 1991; 41: 146-165
6. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-332 (Pubitemid 30117736)
7. Barnes DM, Hanby AM. Estrogen and Progesterone receptors in breast cancer: past, present and future. Histopathology 2001; 38: 271-274 (Pubitemid 32862737)
8. Haider W, Arain GM, Sohu KM, Naqi SA, Younus BB. Estrogen receptors as tumour markers in malignant breast disease: A retrospective study of 100 cases. Biomedica 2001; 17:1-5.
9. Maki DD, Grossman RI. Patterns of disease in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. Am J Neuro Radiol 2000; 21: 1064-1066
10. Salmon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987; 235: 177-182
11. HER-2/neu expression in cancer: The pathologist as diagnostician or Prophet? (Editorial). Hum Pathol 2003; 34:635-638 (Pubitemid 36875507)
12. Iguchi C, Nio Y, Itakura M. Hetrogeneic expression of estrogen receptor between the primary tumour and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implication in patient outcome. J Surg Oncol 2003; 83: 85-93. (Pubitemid 36667416)
13. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 1995; 103: 20-24
14. Schulze MH, Buchmann J. Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases-immunohistochemical investigations of routine formaline-fixed paraffin-embedded tissues. Zentralbl Gynakol 2001; 122: 92-95
15. Von Agthoven T, Timmermans M, Dorssers LC, Hanzen-Logmans SC. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer 1995; 63: 790-793
16. Tuziak T, Olszewski WP, Olszewki W, Pienkowski T. Expression of HER-2/neu in primary and metastatic breast cancer. Pol J Pathol 2001; 52: 21-26 (Pubitemid 32634329)
17. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-5348 (Pubitemid 32694907)
18. Detre S,Saccani JG, Dowsett M. A "quickscore" method for immunohistochemical semiquantification: validation for estrogen receptor in breast carcinoma. J Clin Pathol 1995; 48: 876-878
19. R Development Core Team (2005) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. (Online) Available from URL: http://www.R-project.org.
20. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast carcinoma.Cancer 1983; 52: 479-485
21. Mori T, Moriomoto T, Komaki K, Monden Y. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 1991; 68: 532-537
22. Klinga K, Kaufmann M, Runnebaum B, Kubli F. Distribution of estrogen and progesterone receptors on primary tumour and lymph nodes in individual patients with breast cancer. Oncology 1982; 39:337-339 (Pubitemid 12035233)
23. Cianga C, Cianga P, Cozma L, Diaconu E. Loss of hormonal receptors expression from primarybreast carcinoma to axillary lymph node metastases. Rev Med Chir Soc Med Nat Iasi 2003; 107: 540-544
24. Hoehn JL, PLotka ED, Dickson KB. Comparison of estrogen receptor levels in primary and metastatic carcinoma of the breast. Ann Surg 1979; 190: 69-71. (Pubitemid 9247321)
25. Castagnetta L, Traina A, Di Carlo A, Latteri AM, Carruba G, Leake R. Heterogeneity of soluble and nuclear estrogen receptor status of involved lymph nodes in relation to primary breast cancer. Eur J Cancer Clin Oncol 1987; 23: 31-35 (Pubitemid 17228035)
26. Shimizu S, Fukutomi T, Tsuda H. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissue. J Surg Oncol 2000; 73: 17-20. (Pubitemid 30067528)
27. Masood S, Bui MM. Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000; 30: 259-265 (Pubitemid 30620800)